300723 一品红
已收盘 12-26 15:00:00
资讯
新帖
简况
一品红（300723）披露全资子公司获得丙戊酸钠注射用浓溶液注册证书，12月23日股价下跌3.14%
证券之星 · 12-23
一品红（300723）披露全资子公司获得丙戊酸钠注射用浓溶液注册证书，12月23日股价下跌3.14%
一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书
智通财经 · 12-23
一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书
一品红（300723）披露收到控股股东支持公司发展承诺暨关联交易，12月22日股价上涨2.95%
证券之星 · 12-22
一品红（300723）披露收到控股股东支持公司发展承诺暨关联交易，12月22日股价上涨2.95%
一品红最新公告：控股股东承诺无偿转让Arthrosi9.07%股权净收益以支持公司发展
证券之星 · 12-22
一品红最新公告：控股股东承诺无偿转让Arthrosi9.07%股权净收益以支持公司发展
一品红（300723）披露首次回购公司股份公告，12月18日股价上涨4.14%
证券之星 · 12-18
一品红（300723）披露首次回购公司股份公告，12月18日股价上涨4.14%
一品红：公司高度重视市值管理
证券之星 · 12-18
一品红：公司高度重视市值管理
【机构调研记录】景顺长城基金调研扬农化工、一品红
证券之星 · 12-17
【机构调研记录】景顺长城基金调研扬农化工、一品红
【机构调研记录】安信基金调研佰维存储、一品红
证券之星 · 12-17
【机构调研记录】安信基金调研佰维存储、一品红
【机构调研记录】华泰保兴基金调研一品红
证券之星 · 12-17
【机构调研记录】华泰保兴基金调研一品红
【私募调研记录】青骊投资调研百傲化学、一品红
证券之星 · 12-17
【私募调研记录】青骊投资调研百傲化学、一品红
【私募调研记录】永安国富调研景嘉微、一品红
证券之星 · 12-17
【私募调研记录】永安国富调研景嘉微、一品红
12月16日一品红跌10.45%，广发医疗保健股票A基金重仓该股
证券之星 · 12-16
12月16日一品红跌10.45%，广发医疗保健股票A基金重仓该股
一品红：持有AR882中国地区100%市场权益
证券之星 · 12-16
一品红：持有AR882中国地区100%市场权益
一品红：拟以1亿至2亿元回购公司股份
新京报 · 12-16
一品红：拟以1亿至2亿元回购公司股份
一品红盘中跌逾12%
北京商报 · 12-16
一品红盘中跌逾12%
一品红最新公告：拟最高或达15亿美元出售参股公司美国Arthrosi公司13.45%股权
证券之星 · 12-15
一品红最新公告：拟最高或达15亿美元出售参股公司美国Arthrosi公司13.45%股权
一品红（300723）披露关于参股公司美国Arthrosi被并购的提示性公告，12月15日股价下跌20.0%
证券之星 · 12-15
一品红（300723）披露关于参股公司美国Arthrosi被并购的提示性公告，12月15日股价下跌20.0%
12月15日一品红（300723）龙虎榜数据：机构净卖出7066.53万元，北向资金净买入520.1万元
证券之星 · 12-15
12月15日一品红（300723）龙虎榜数据：机构净卖出7066.53万元，北向资金净买入520.1万元
异动快报：一品红（300723）12月15日9点40分触及跌停板
证券之星 · 12-15
异动快报：一品红（300723）12月15日9点40分触及跌停板
一品红最新公告：参股公司美国Arthrosi拟被并购
证券之星 · 12-14
一品红最新公告：参股公司美国Arthrosi拟被并购
加载更多
公司概况
公司名称：
一品红药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2017-11-16
主营业务：
一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。
发行价格：
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":34.79,"timestamp":1766732616000,"preClose":35.67,"halted":0,"volume":11511636,"delay":0,"changeRate":-0.0247,"floatShares":418000000,"shares":451999999,"eps":-0.9511,"marketStatus":"已收盘","change":-0.88,"latestTime":"12-26 15:00:00","open":35.45,"high":35.58,"low":34.48,"amount":401000000,"amplitude":0.0308,"askPrice":34.8,"askSize":283,"bidPrice":34.79,"bidSize":121,"shortable":0,"etf":0,"ttmEps":-0.9511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":35.67,"symbolType":"stock","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":39.24,"lowLimit":32.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":9.2,"roa":"--","roe":"--","epsLYR":-1.1956,"committee":-0.331307,"marketValue":15714000000,"turnoverRate":0.0276,"status":1,"floatMarketCap":14531000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2593241566","title":"一品红（300723）披露全资子公司获得丙戊酸钠注射用浓溶液注册证书，12月23日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593241566","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593241566?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:18","pubTimestamp":1766499513,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，一品红报收于35.5元，较前一交易日下跌3.14%，最新总市值为160.35亿元。该股当日开盘36.8元，最高37.85元，最低34.92元，成交额达7.26亿元，换手率为4.86%。公司近日发布公告称，其全资子公司广州市联瑞制药有限公司收到国家药品监督管理局签发的丙戊酸钠注射用浓溶液《药品注册证书》。药品有效期24个月，批准文号有效期至2030年12月15日。此次获批将丰富公司产品管线，增强慢病药领域竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300040108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2593092467","title":"一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593092467","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593092467?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:55","pubTimestamp":1766476503,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州市联瑞制药有限公司于近日收到国家药品监督管理局核准签发的关于丙戊酸钠注射用浓溶液的《药品注册证书》。此次公司获得丙戊酸钠注射用浓溶液注册证书，标志着公司具备了在国内市场销售该规格药品的资格，将进一步丰富公司产品管线和产品品类，增强了公司在慢病药的竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)子公司获得丙戊酸钠注射用浓溶液注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2593486846","title":"一品红（300723）披露收到控股股东支持公司发展承诺暨关联交易，12月22日股价上涨2.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593486846","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593486846?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:54","pubTimestamp":1766397277,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，一品红报收于36.65元，较前一交易日上涨2.95%，最新总市值为165.55亿元。该事项构成关联交易，但属于公司单方面获得利益且不支付对价的情形，无需提交股东会审议。同日，公司召开第四届董事会第十五次会议，审议通过《关于收到控股股东支持公司发展承诺暨关联交易的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2593855094","title":"一品红最新公告：控股股东承诺无偿转让Arthrosi9.07%股权净收益以支持公司发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2593855094","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593855094?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:44","pubTimestamp":1766396658,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司控股股东广东广润集团有限公司承诺，待Arthrosi Therapeutics,Inc.被并购交易完成后，将其子公司持有的Arthrosi 9.07%股权按照E轮投资后的净收益无偿给予公司，以支持公司研发创新发展。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200021992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2592710809","title":"一品红（300723）披露首次回购公司股份公告，12月18日股价上涨4.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592710809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592710809?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:47","pubTimestamp":1766051256,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，一品红报收于34.72元，较前一交易日上涨4.14%，最新总市值为156.83亿元。该股当日开盘33.61元，最高35.47元，最低33.35元，成交额达8.99亿元，换手率为6.24%。根据公司于近日发布的公告，一品红药业集团股份有限公司于2025年12月17日首次通过集中竞价方式回购公司股份，回购股份数量为706,000股，占公司总股本的0.16%。本次回购符合相关法律法规及公司既定回购方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800027050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2592207389","title":"一品红：公司高度重视市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592207389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592207389?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:15","pubTimestamp":1766042126,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红12月18日在投资者关系平台上答复投资者关心的问题。公司高重视市值管理和投资者关系管理工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800017567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2592304956","title":"【机构调研记录】景顺长城基金调研扬农化工、一品红","url":"https://stock-news.laohu8.com/highlight/detail?id=2592304956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592304956?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:11","pubTimestamp":1765930313,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月16日披露的机构调研信息，景顺长城基金近期对2家上市公司进行了调研，相关名单如下：1）扬农化工 调研纪要：当前农药行业整体仍处于周期调整阶段，供给充足制约价格上行，预计价格将在底部震荡。氟螨双醚登记待批，预计2026年推向市场。2）一品红 调研纪要：此次交易包括9.5亿美元首付款和最高5.5亿美元里程碑付款，预计2026年一季度完成交割。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700003926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0229","300723","600486"],"gpt_icon":0},{"id":"2592495665","title":"【机构调研记录】安信基金调研佰维存储、一品红","url":"https://stock-news.laohu8.com/highlight/detail?id=2592495665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592495665?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:11","pubTimestamp":1765930299,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月16日披露的机构调研信息，安信基金近期对2家上市公司进行了调研，相关名单如下：1）佰维存储 调研纪要：公司在AI端侧存储具备较强竞争力，布局AI手机、AI PC、AI眼镜等高毛利业务，是业内率先抓住AI眼镜机遇的厂商。已量产UFS、LPDDR5/5X等产品，预计2025年AI眼镜收入同比增长超500%。2）一品红 调研纪要：此次交易包括9.5亿美元首付款和最高5.5亿美元里程碑付款，预计2026年一季度完成交割。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700003910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0214","688525","BK0239"],"gpt_icon":0},{"id":"2592956582","title":"【机构调研记录】华泰保兴基金调研一品红","url":"https://stock-news.laohu8.com/highlight/detail?id=2592956582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592956582?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:11","pubTimestamp":1765930291,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月16日披露的机构调研信息，华泰保兴基金近期对1家上市公司进行了调研，相关名单如下：1）一品红 调研纪要：此次交易包括9.5亿美元首付款和最高5.5亿美元里程碑付款，预计2026年一季度完成交割。华泰保兴基金成立于2016年，截至目前，资产管理规模621.98亿元，排名79/211；资产管理规模542.1亿元，排名73/211；管理公募基金数64只，排名92/211；旗下公募基金经理13人，排名94/211。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700003899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2592566149","title":"【私募调研记录】青骊投资调研百傲化学、一品红","url":"https://stock-news.laohu8.com/highlight/detail?id=2592566149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592566149?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:11","pubTimestamp":1765930272,"startTime":"0","endTime":"0","summary":"根据市场公开信息及12月16日披露的机构调研信息，知名私募青骊投资近期对2家上市公司进行了调研，相关名单如下：1）百傲化学 调研纪要：半导体设备业务是公司未来重要战略发展方向。公司已战略控股芯慧联并参股芯慧联新，大股东协议转让正有序推进。目前未开展光刻机售后服务。2）一品红 调研纪要：此次交易包括9.5亿美元首付款和最高5.5亿美元里程碑付款，预计2026年一季度完成交割。中国专利到期2037年，可延至2042年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025121700003875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","603360","300723","BK0239"],"gpt_icon":0},{"id":"2592956590","title":"【私募调研记录】永安国富调研景嘉微、一品红","url":"https://stock-news.laohu8.com/highlight/detail?id=2592956590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592956590?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:11","pubTimestamp":1765930267,"startTime":"0","endTime":"0","summary":"根据市场公开信息及12月16日披露的机构调研信息，知名私募永安国富近期对2家上市公司进行了调研，相关名单如下：1）景嘉微 调研纪要：CH37系列已顺利完成流片、封装、回片及点亮，提供64TOPS@INT8峰值算力，集成CPU、GPU、NPU、GPGPU、ISP等单元，具备高算力、低功耗、多传感处理优势。2）一品红 调研纪要：此次交易包括9.5亿美元首付款和最高5.5亿美元里程碑付款，预计2026年一季度完成交割。中国专利到期2037年，可延至2042年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025121700003869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300474","BK0089","BK0038","BK0239","BK0125","BK0037","BK0198","300723","BK0214"],"gpt_icon":0},{"id":"2591601809","title":"12月16日一品红跌10.45%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591601809","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591601809?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:41","pubTimestamp":1765870887,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日一品红跌10.45%创60日新低，收盘报33.42元，换手率10.34%，成交量43.19万手，成交额14.39亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为51.85亿元，最新净值1.8205，较上一交易日下跌3.07%，近一年上涨8.66%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591609947","title":"一品红：持有AR882中国地区100%市场权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2591609947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591609947?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:24","pubTimestamp":1765869867,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司，能不能详细解释一下子公司被收购公告，市场误读为失去中国市场和优先生产权？一品红回复：尊敬的投资者您好，感谢您对公司的关注。交易完成后，公司持有AR882在中国地区（含香港、澳门和中国台湾）100%市场权益，以及拥有优先给Arthrosi提供AR882的全球生产供应权。交易的具体信息请参阅公司披露的相关公告。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600019770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591717146","title":"一品红：拟以1亿至2亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591717146","media":"新京报","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591717146?lang=zh_cn&edition=full","pubTime":"2025-12-16 10:32","pubTimestamp":1765852320,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 12月15日，一品红发布公告称，公司将使用自有资金以集中竞价方式回购公司股份。本次回购的股份用于维护公司价值及股东权益；回购资金总额不低于1亿元且不超过2亿元，回购股份价格不超过70元/股（含），未超过公司董事会通过回购股份决议前三十个交易日公司股票交易均价150%。本次回购股份的实施期限自公司董事会审议通过本次回购方案之日起3个月内。","market":"hk","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/chenzw202512161032542833383.png?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/chenzw202512161032542833383.png?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1765852375168296.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1765852375168296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591434672","title":"一品红盘中跌逾12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591434672","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591434672?lang=zh_cn&edition=full","pubTime":"2025-12-16 10:28","pubTimestamp":1765852080,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）拟回购股份的消息未能提振公司股价，12月16日，一品红（300723）低开低走，盘中一度跌逾12%。 交易行情显示，12月16日，一品红低开4.34%，盘中股价震荡走低，截至北京商报记者发稿，一品红报32.82元/股，跌幅为12.06%。（文章来源：北京商报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-16/doc-inhayftq0127323.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-16/doc-inhayftq0127323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591643058","title":"一品红最新公告：拟最高或达15亿美元出售参股公司美国Arthrosi公司13.45%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643058","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591643058?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:49","pubTimestamp":1765799387,"startTime":"0","endTime":"0","summary":"一品红公告称，公司拟通过全资子公司出售参股公司美国Arthrosi Therapeutics, Inc. 13.45%的股权，交易对方为瑞典Swedish Orphan Biovitrum AB下属全资子公司Sobi US Holding Corp.。交易总价最高或达15亿美元，包括9.5亿美元首付款和最高5.5亿美元的里程碑付款。交易完成后，公司将不再持有Arthrosi股权。本次交易尚需提请公司股东会审议批准。预计本次出让股权将对公司产生积极影响，最终对公司利润的影响金额以会计师审计确认后的数据为准。回购价格不超过70元/股，用于维护公司价值及股东权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500029535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2591175936","title":"一品红（300723）披露关于参股公司美国Arthrosi被并购的提示性公告，12月15日股价下跌20.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591175936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591175936?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:57","pubTimestamp":1765792640,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，一品红报收于37.32元，较前一交易日下跌20.0%，最新总市值为168.57亿元。公司于近日发布关于参股公司美国Arthrosi被并购的提示性公告。公告显示，一品红药业集团股份有限公司通过全资子公司持有美国Arthrosi公司13.45%股权。Sobi美国拟以9.5亿美元首付款及最高5.5亿美元里程碑付款收购Arthrosi 100%股权，交易需经Arthrosi股东会批准。公司持有AR882在中国地区100%市场权益，并优先拥有全球生产供应权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500023337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2591612216","title":"12月15日一品红（300723）龙虎榜数据：机构净卖出7066.53万元，北向资金净买入520.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612216?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:52","pubTimestamp":1765792373,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年12月15日公布的交易公开信息显示，一品红因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年12月15日收盘，一品红报收于37.32元，下跌20.0%，跌停，换手率4.03%，成交量16.85万手，成交额6.3亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出7066.53万元，北向资金合计净买入520.1万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500022819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2591695143","title":"异动快报：一品红（300723）12月15日9点40分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2591695143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591695143?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:41","pubTimestamp":1765762863,"startTime":"0","endTime":"0","summary":"证券之星12月15日盘中消息，9点40分一品红（300723）触及跌停板。其所属行业化学制药目前下跌。领涨股为花园生物。该股为中药，疫苗，创新药概念热股。12月12日的资金流向数据方面，主力资金净流出3176.66万元，占总成交额9.66%，游资资金净流入2041.87万元，占总成交额6.21%，散户资金净流入1134.8万元，占总成交额3.45%。近5日资金流向一览见下表：一品红主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500002448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2591650759","title":"一品红最新公告：参股公司美国Arthrosi拟被并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650759","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650759?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:59","pubTimestamp":1765702770,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司参股的美国Arthrosi Therapeutics,Inc.（简称：“Arthrosi”）收到Sobi美国发出的相关协议条款，Sobi美国拟以9.5亿美元首付款（折合人民币约67.13亿元），以及最高达5.5亿美元（折合人民币约38.87亿元）的临床、注册和销售里程碑付款收购Arthrosi 100%股权。公司通过全资子公司瑞腾生物(香港)有限公司持有Arthrosi 13.45%的股权。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400005009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766853793559,"stockEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.3504},{"period":"3month","weight":-0.3759},{"period":"6month","weight":-0.289},{"period":"1year","weight":0.8836},{"period":"ytd","weight":1.0393}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20363人(较上一季度减少1.73%)","perCapita":"20511股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}